RxDoctor Payments Data

Krystle Phillips

Physician Assistant · Homewood, ALNPI 1831633098

Payments from drug & device makers

$3,831in general payments, 2019–2025

Across 152 payments — averaging $25.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$658
  • Johnson & Johnson$584
  • Antares Pharma, Inc.$483
  • Urovant Sciences Inc$217
  • Pfizer$216
  • Astellas Pharma US Inc$199
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,76098%
  • Education$712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,831 in reported general payments places this provider in the 85th percentile of 846 physician assistant providers in Alabama.

See all physician assistant providers in Alabama

Medicare billing

Part B allowed, 2024
$52,787
Medicare patients
330
Services billed
6,391

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron184$147,972
MyrbetriqMirabegron95$54,137
Estradiol194$14,875
XyostedTestosterone Enanthate18$10,999
YuvafemEstradiol30$3,642
Tamsulosin Hcl227$2,562
Potassium Citrate ErPotassium Citrate30$2,302
Alfuzosin Hcl ErAlfuzosin Hcl99$1,616
Finasteride109$1,377
NitrofurantoinNitrofurantoin Macrocrystal34$1,291
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst61$979
Cefdinir57$820
Methenamine Hippurate15$589
Bethanechol Chloride11$417
Ciprofloxacin Hcl56$328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$658$147,972184 claims
Astellas Pharma US IncMyrbetriq$199$54,13795 claims
Antares Pharma, Inc.Xyosted$483$10,99918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 846 physician assistant providers in Alabama.

Other physician assistant in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →